Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)

NCT04146896 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

228

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Peripheral Neuropathic Pain

Interventions

DRUG: NYX-2925 50 mg
DRUG: Placebo

Sponsor

Aptinyx

Collaborators

[object Object]